Zunsemetinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Zunsemetinib
- Molecular weight
- 513.93
- Structure (SMILES)
- Cc1cnc(-c2ccnc(C(C)(C)O)n2)cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O
- ati 450
- Ati 450
- ATI 450 [WHO-DD]
- ati 450 20 mg oral tablet bid
- ati 450 50 mg oral tablet bid
- ati 450 who dd
- ATI-450
- ATI-450 20 mg oral tablet BID
- ATI-450 50 mg oral tablet BID
- ati450
- ATI450
- cdd 450
- CDD-450
- cdd450
- CDD450
- zunsemetinib
- Zunsemetinib
- zunsemetinib [INN]
- ZUNSEMETINIB [USAN]
- zunsemetinib inn
- zunsemetinib usan
- CAS registry numbers
- 1640282-42-3
- ChEMBL ID
- CHEMBL3704901
- InChIKey
- FQPQMJULRZINPV-UHFFFAOYSA-N
- PubChem compound IDs
- 86291496
- FDA ingredient codes (UNII)
- AX2VWG0ZCR
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- zunsemetinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Arthritis, Psoriatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003778
- Subject identifier
- D015535
- Condition
- Hidradenitis Suppurativa
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000710
- Subject identifier
- D017497
- Condition
- Cryopyrin-Associated Periodic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0016168
- Subject identifier
- D056587
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition
- Inflammation
- Highest recorded phase
- 1
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003778
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000710
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011849
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0016168
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- Condition identifier
- MP_0001845
- NCT04247815
- NCT05279417
- NCT04481685
- NCT04524858
- NCT05216224
- NCT05511519
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 103.02
- Calculated partition coefficient (ALogP)
- 4.44
- Calculated partition coefficient (XLogP)
- 2.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 6
- Heavy atoms
- 36
- Molecular formula
- C25H22ClF2N5O3
- Monoisotopic mass
- 513.1379236
- Natural product
- No
- Recorded assays
- 40
- Active assays
- 12
Active assay types
- Confirmatory
Solubility
- Median
- 5.6
- Mean
- 5.6
- Minimum
- 5.6
- Maximum
- 5.6
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 72
- Mean
- 72
- Minimum
- 71
- Maximum
- 73
- Unit
- %
- Assays
- 2
- Standard deviation
- 1.41421
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (8)
- A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
- ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
- ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
- MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
- Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA
- Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
In development for (7)
- Breast cancer Phase 1
- COVID-19 Phase 2
- Cryopyrin-associated periodic syndrome Phase 2
- Hidradenitis suppurativa Phase 2
- Pancreatic ductal adenocarcinoma Phase 1
- Psoriatic arthritis Phase 2
- Rheumatoid arthritis Phase 2